-
公开(公告)号：US20200010471A1
公开(公告)日：2020-01-09
申请号：US16306647
申请日：2017-06-05
发明人： Qingsong LIU , Jing LIU , Xixiang LI , Aoli WANG , Ziping QI , Hong WU , Jiaxin WU , Wenchao WANG , Chen HU , Cheng CHEN , Li WANG , Beilei WANG
IPC分类号： C07D487/04 , A61P35/02
摘要： The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase).
-
2.发明公开公开(公告)号：US20230235283A1
公开(公告)日：2023-07-27
申请号：US17918971
申请日：2020-04-23
发明人： Qingsong LIU , Jie HU , Wenchao WANG , Cheng CHEN , Tao REN , Li WANG
CPC分类号： C12N5/0625 , C12N5/0693 , C12N2501/11 , C12N2500/25 , C12N2501/727 , C12N2501/12 , C12N2501/15 , C12N2503/02
摘要： Provided are a primary cell culture medium that contains a combination of an MST1/2 kinase inhibitor and a ROCK kinase inhibitor and is used for culturing primary esophageal squamous cell carcinoma epithelial cells, and a culture method using the primay cell culture medium. In the culture method, the primary cell culture medium is used to culture primay cells on a culture vessel coated with an extracellular matrix glue, so that the primary cells prolilferate rapidly. A cell model obtained by using the primary cell culture medium and the primary cell culture method of the present invention can be used for the efficacy evaluation and screening of drugs.
-
3.发明申请公开(公告)号：US20230091960A1
公开(公告)日：2023-03-23
申请号：US17798640
申请日：2020-02-26
发明人： Qingsong LIU , Jie HU , Cheng CHEN , Wenchao WANG , Li WANG
摘要： Provided are a culture medium and cultivation method of rapidly expanding primary cells of esophageal squamous carcinoma in vitro, and the use thereof in screening drugs. The culture medium comprises an initial culture medium selected from DMEM/F12, DMEM, F12, or RPMI-1640, a Rho protease inhibitor, an antibiotic, insulin, an N2 additive, insulin-like growth factor 1, a non-essential amino acid, and optionally, hydrocortisone, optionally, glutamine, and optionally, bovine pituitary extract.
-
4.发明公开公开(公告)号：US20240319169A1
公开(公告)日：2024-09-26
申请号：US18271773
申请日：2021-01-22
发明人： Qingsong LIU , Feiyang LIU , Xiaoyu LI , Husheng MEI , Wenchao WANG , Tao REN , Li WANG
CPC分类号： G01N33/5011 , C12N5/0693 , C12N2501/115 , C12N2501/119 , C12N2501/125 , C12N2501/135 , C12N2501/345 , C12N2533/54
摘要： The present invention provides a cell culture medium for culturing primary gastrointestinal stromal tumor cells, comprising gastrin, N2, insulin, a receptor tyrosine kinase ligand, and a Rock kinase inhibitor. The present invention further provides a method for culturing gastrointestinal stromal tumor cells by using the cell culture medium, and an application and a method of an expanded cell population, which is obtained by using the method, in efficacy evaluation or screening.
-
公开(公告)号：US20190084960A1
公开(公告)日：2019-03-21
申请号：US16089547
申请日：2017-03-28
发明人： Qingsong LIU , Jing LIU , Qiang WANG , Beilei WANG , Feiyang LIU , Shuang QI , Ziping QI , Fengming ZOU , Cheng CHEN , Wenchao WANG , Chen HU , Xiaochuan LIU , Wei WANG , Aoli WANG , Li WANG , Zhenquan HU , Tao REN
IPC分类号： C07D401/06 , A61K31/4545 , C07D211/44 , A61K31/445 , C07D413/06 , A61K31/454 , C07D401/14 , C07D409/14 , A61P35/00
摘要： The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.
-
6.发明公开公开(公告)号：US20240344020A1
公开(公告)日：2024-10-17
申请号：US18577457
申请日：2021-07-28
发明人： Qingsong LIU , Jie HU , Tao HUANG , Cheng CHEN
CPC分类号： C12N5/0018 , C12N5/0693 , C12N2501/105 , C12N2501/117 , C12N2501/12 , C12N2501/2306 , C12N2501/999 , C12N2503/02
摘要： A primary cell culture medium for culturing primary lung cancer epithelial cells, containing an MST1/2 kinase inhibitor, a ROCK inhibitor, fibroblast growth factor 7, at least one additive of B27 additive and N2 additive, hepatocyte growth factor, insulin-like growth factor 1, interleukin 6, and a TGFβ type I receptor inhibitor. The invention also relates to a culture method using the primary cell culture medium and its application in the efficacy evaluating and screening of drugs. In the culture method, the primary cell culture medium is used to culture primary cells in a culture vessel coated with an extracellular matrix gel, to make the primary cells expend rapidly. A cell model obtained using the primary cell culture medium and the primary cell culture method can be used for the efficacy evaluating and screening of drugs.
-
公开(公告)号：US20240319170A1
公开(公告)日：2024-09-26
申请号：US18275125
申请日：2021-02-05
发明人： Qingsong LIU , Yuying HE , Cheng CHEN , Tao HUANG , Tao REN , Wenchao WANG , Li WANG
CPC分类号： G01N33/5011 , C12N5/0693 , C12N2500/02 , C12N2501/01 , C12N2501/105 , C12N2501/11 , C12N2501/115 , C12N2501/117 , C12N2501/119 , C12N2501/12 , C12N2501/2322 , C12N2509/00
摘要： Disclosed are a culture medium and a culture method for in vitro expansion of primary cells of intestinal cancer. The culture medium comprises an initial culture medium, a Rho protease inhibitor, an antibiotic, gastrin, A8301, a non-essential amino acid, cholera toxin, an insulin-like growth factor-1, nicotinamide, insulin, fetal bovine serum, and an additive selected from at least one of a B27 additive and an N2 additive. By using the culture medium, effective and rapid expansion of the primary cells of intestinal cancer can be achieved. The expanded cells maintain the pathological characteristics of patients, and the culture success rate and the cell expansion rate of the primary cells of intestinal cancer are improved, which provide a research foundation for personalized treatment of the patients.
-
公开(公告)号：US20220389379A1
公开(公告)日：2022-12-08
申请号：US17775106
申请日：2019-11-18
发明人： Qingsong LIU , Feiyang LIU , Husheng MEI , Wenchao WANG , Ming ZHAO , Zongru JIANG , Tao REN , Li WANG
摘要： Provided is a culture medium containing amphiregulin for culturing primary breast epithelial cells and a culture method involving using the medium. In the culturing method, primary cells are cultured on a culture vessel coated with an extracellular matrix gel by using the culture medium, and the primary cells grow on the culture vessel, which has been coated with the extracellular matrix gel, and proliferate rapidly under the combined action of nutrient factors and an extracellular matrix contained in the primary cell culture medium. The cell model obtained by the primary cell culture medium and the primary cell culture method can be used for the evaluating the efficacy of and screening drugs.
-
公开(公告)号：US20190010159A1
公开(公告)日：2019-01-10
申请号：US16066427
申请日：2016-12-27
发明人： Qingsong LIU , Jing LIU , Xixiang LI , Aoli WANG , Hong WU , Kailin YU , Chen HU , Wenchao WANG , Cheng CHEN , Fengming ZOU , Ziping QI , Li WANG , Beilei WANG
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00
摘要： The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.
-
公开(公告)号：US20180369242A1
公开(公告)日：2018-12-27
申请号：US16062399
申请日：2016-12-15
发明人： Jing LIU , Qingsong LIU , Taoshan JIANG , Aoli WANG , Jiaxin WU , Hong WU , Ziping QI , Yongfei CHEN , Fengming ZOU , Wenchao WANG , Zheng ZHAO , Li WANG , Beilei WANG
IPC分类号： A61K31/506 , A61P35/00 , C07D409/12 , C07D401/12 , C07D239/47 , A61K31/5377 , A61K31/551 , C07D239/48 , C07D403/12
CPC分类号： A61K31/506 , A61K31/5377 , A61K31/551 , A61P35/00 , C07D239/47 , C07D239/48 , C07D401/12 , C07D403/12 , C07D409/12 , Y02P20/55
摘要： The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.022 秒)
